Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
6.99
-0.13 (-1.83%)
At close: Aug 7, 2025, 4:00 PM
6.88
-0.11 (-1.57%)
Pre-market: Aug 8, 2025, 4:26 AM EDT
Longboard Pharmaceuticals Employees
Enanta Pharmaceuticals had 131 employees as of September 30, 2024. The number of employees decreased by 14 or -9.66% compared to the previous year.
Employees
131
Change (1Y)
-14
Growth (1Y)
-9.66%
Revenue / Employee
$492,084
Profits / Employee
-$735,992
Market Cap
149.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | 141 | 9 | 6.82% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENTA News
- 2 days ago - Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - Business Wire
- 23 days ago - Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series - Business Wire
- 2 months ago - Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Business Wire
- 2 months ago - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - Business Wire
- 3 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - Business Wire
- 4 months ago - Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
- 5 months ago - Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Business Wire